Insmed traded at $21.42 this Friday June 24th, increasing $1.57 or 7.91 percent since the previous trading session. Looking back, over the last four weeks, Insmed gained 11.16 percent. Over the last 12 months, its price fell by 25.98 percent. Looking ahead, we forecast Insmed to be priced at 20.84 by the end of this quarter and at 19.21 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
21.42
Daily Change
7.91%
Yearly
-25.98%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AcelRx Pharmaceuticals 0.18 -0.02 -9.73% -87.32%
Alimera Sciences 5.25 -0.25 -4.55% -44.74%
BioMarin Pharmaceutical 86.85 2.30 2.72% 2.43%
Cytokinetics 47.25 -0.22 -0.46% 110.00%
DBV Technologies 2.50 0 0% -56.22%
Dynavax Technologies 12.33 0.05 0.41% 34.02%
Gilead Sciences 63.08 0.50 0.80% -7.07%
Heron Therapeutics 3.40 0.04 1.19% -79.54%
Insmed 21.42 1.57 7.91% -25.98%
Mirati Therapeutics 68.16 2.27 3.45% -58.51%
Novartis 84.83 2.97 3.63% -8.28%
Iveric bio Inc. 10.44 0.47 4.71% 71.43%
Ultragenyx Pharmaceutical 60.57 0.58 0.97% -35.45%
Regeneron Pharmaceuticals 612.49 5.10 0.84% 11.25%
Seattle Genetics 179.33 5.33 3.06% 14.09%
Sarepta Therapeutics 75.22 3.40 4.73% -6.44%
Vertex Pharmaceuticals 292.55 9.05 3.19% 50.54%

Indexes Price Day Year
USND 11608 375.43 3.34% -19.17%
US2000 1766 54.06 3.16% -24.36%

Insmed
Insmed Incorporated is a global biopharmaceutical company. The Company's product, ARIKAYCE (amikacin liposome inhalation suspension) is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders.